These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. Albini A; Pennesi G; Donatelli F; Cammarota R; De Flora S; Noonan DM J Natl Cancer Inst; 2010 Jan; 102(1):14-25. PubMed ID: 20007921 [TBL] [Abstract][Full Text] [Related]
15. Cardiovascular adverse drug reaction associated with combined beta-adrenergic and calcium entry-blocking agents. Edoute Y; Nagachandran P; Svirski B; Ben-Ami H J Cardiovasc Pharmacol; 2000 Apr; 35(4):556-9. PubMed ID: 10774785 [TBL] [Abstract][Full Text] [Related]
16. A potential role for glucagon in the treatment of drug-induced symptomatic bradycardia. Love JN; Sachdeva DK; Bessman ES; Curtis LA; Howell JM Chest; 1998 Jul; 114(1):323-6. PubMed ID: 9674488 [TBL] [Abstract][Full Text] [Related]
17. β-Blockers, Cocaine, and the Unopposed α-Stimulation Phenomenon. Richards JR; Hollander JE; Ramoska EA; Fareed FN; Sand IC; Izquierdo Gómez MM; Lange RA J Cardiovasc Pharmacol Ther; 2017 May; 22(3):239-249. PubMed ID: 28399647 [TBL] [Abstract][Full Text] [Related]
18. Rate-control treatment and mortality in atrial fibrillation. Chao TF; Liu CJ; Tuan TC; Chen SJ; Wang KL; Lin YJ; Chang SL; Lo LW; Hu YF; Chen TJ; Chiang CE; Chen SA Circulation; 2015 Oct; 132(17):1604-12. PubMed ID: 26384160 [TBL] [Abstract][Full Text] [Related]
19. Advantages of beta blockers versus antiarrhythmic agents and calcium antagonists in secondary prevention after myocardial infarction. Singh BN Am J Cardiol; 1990 Sep; 66(9):9C-20C. PubMed ID: 1699400 [TBL] [Abstract][Full Text] [Related]
20. Misuse of 'toxin'. Dayan AD Clin Med (Lond); 2008 Apr; 8(2):230. PubMed ID: 18478882 [No Abstract] [Full Text] [Related] [Next] [New Search]